- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Elicera Therapeutics receives partial payment of 0,5 MEur from EIC | 3 | Cision News | ||
| 12.02. | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme | 1 | Cision News | ||
| 10.02. | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans | 8 | Cision News | ||
| 05.02. | ELICERA THERAPEUTICS: Elicera's CEO: "2025 is a crucial year for us" | 1 | Cision News | ||
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 64 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.01. | ELICERA THERAPEUTICS: Elicera's CEO: "All signs of the disease disappeared in the first patient" | 1 | Cision News | ||
| 21.01. | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference | 2 | Cision News | ||
| 15.01. | ELICERA THERAPEUTICS: Elicera's candidate ELC-100 granted Orphan Drug Designation | 4 | Cision News | ||
| 13.01. | Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors | 2 | Cision News | ||
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 68 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen | |
| 27.11.24 | ELICERA THERAPEUTICS: Elicera's CEO: "ELC-100 stands apart from all other standard treatments" | 1 | Cision News | ||
| 12.11.24 | ELICERA THERAPEUTICS: Elicera's CEO: "One of the biggest milestones in our history" | 1 | Cision News | ||
| 05.11.24 | Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma | 1 | Cision News | ||
| 04.11.24 | Elicera Therapeutics will present at the BioStock Life Science Summit, November 20 | 5 | Cision News | ||
| 24.10.24 | Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100 | 3 | Cision News | ||
| 03.09.24 | Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall | 2 | Cision News | ||
| 29.08.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2024 | 47 | GlobeNewswire (Europe) | Second quarter (April-June 2024)
Operating profit/loss amounted to SEK -5,841,409 (-4 466 286).
Loss for the period amounted to SEK -5,622,779 (-4,335,852).
Cash flow from operating activities... ► Artikel lesen | |
| 27.05.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2024 | 351 | GlobeNewswire (Europe) | First quarter (January-March 2024)
Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857).
Loss for the period amounted to SEK - 5,369,677 (-2,266,329).
Cash flow from operating activities... ► Artikel lesen | |
| 14.05.24 | Nasdaq Stockholm AB: Change of Certified Adviser for Elicera Therapeutics AB | 241 | GlobeNewswire | As from May 15, 2024, Elicera Therapeutics AB (publ) will change Certified
Adviser to Mangold Fondkommission AB.
This information is distributed at the request of the Certified Adviser,
Carnegie... ► Artikel lesen | |
| 04.04.24 | Nasdaq Stockholm AB: New equity right for trading, Elicera Therapeutics AB TO2 | 302 | GlobeNewswire | At the request of Elicera Therapeutics AB, Elicera Therapeutics AB equity
rights will be traded on First North Growth Market as from April 5, 2024.
Security name: Elicera Therapeutics AB TO2
-------------------------------------------
Short... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,520 | -0,35 % | Evotec-Aktie kann Vortagsniveau nicht halten (8,49 €) | An der deutschen Börse liegt die Evotec-Aktie derzeit im Minus. Der jüngste Kurs betrug 8,49 Euro. Am Aktienmarkt liegt die Evotec-Aktie aktuell im Minus. Das Wertpapier verbilligte sich um 24 Cent.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 673,40 | +0,51 % | Dividendenbekanntmachungen (20.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCED INFO SERVICE PCL TH0268010Z11 5,74 THB 0,1632 EUR ADVANCED INFO SERVICE PCL NVDR TH0268010R11 5,74 THB 0,1632 EUR ALUMASC... ► Artikel lesen | |
| BRAIN BIOTECH | 2,880 | +1,05 % | EQS-News: BRAIN Biotech AG: Biologisches Goldrecycling: BRAIN Biotech AG kooperiert mit PX Group im Rahmen der "PX Urban Mining Initiative" | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Kooperation/Nachhaltigkeit
Biologisches Goldrecycling: BRAIN Biotech AG kooperiert mit PX Group im Rahmen der "PX Urban Mining Initiative"... ► Artikel lesen | |
| SCORPIUS | 0,202 | -1,32 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,168 | +1,39 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for th | Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,071 | +11,56 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 154,94 | -0,31 % | Japan's MHLW approves CSL Behring's Andembry to stop HAE attacks | ||
| MANNKIND | 5,528 | +0,47 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,408 | -0,98 % | Research and Markets: Europe Genome Sequencing Market Analysis and Forecasts 2024 & 2025-2033, Competition Synopsis of Eurofins Scientific, F. Hoffmann-La Roche, OncoDNA, Oxford Nanopore Technologies, and QIAGEN - ResearchAndMarkets.com | The "Europe Genome Sequencing Market: Focus on Product, End User, and Country Analysis and Forecast: 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe genome sequencing... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,758 | +1,05 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to redefining the retina experience, today... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,525 | -1,87 % | Adaptimmune Therapeutics PLC: Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor... ► Artikel lesen | |
| CODEXIS | 3,958 | -1,44 % | Codexis Aktie: Ruhe vor der nächsten Bewegung? | Die kalifornische Biotechnologie-Firma Codexis steht vor wichtigen Terminen Ende Februar. Am 27. Februar 2025 wird das Unternehmen seine Geschäftsergebnisse für das vierte Quartal 2024 nachbörslich... ► Artikel lesen | |
| TELO GENOMICS | 0,051 | +50,00 % | Telo Genomics Corp.: Telo Genomics Closes Oversubscribed $2.5 Million Private Placement | Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,260 | 0,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth | Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora... ► Artikel lesen | |
| CORMEDIX | 9,800 | +1,03 % | CorMedix, Inc.: CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update | ? Q4 2024 Unaudited Net Revenue of Approximately $31mm ? ? FY 2024 Unaudited Net Revenue of Approximately $43mm ? ? Expects Q4 Adjusted EBITDA to Exceed $12mm ? BERKELEY HEIGHTS, N.J., Jan. 07, 2025... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,005 (-2,27 %) liegt der Kurs bei 0,194 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.
